TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.
Previous Post
Chaisson Briefs Congress on Lifesaving NIH Infectious Disease Research
Next Post
Closing a zombie biotech, and Lilly’s disappointing obesity readout
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago